Comparative efficacy and safety of novel immuno-chemotherapy for extensive-stage small-cell lung cancer: a network meta-analysis of randomized controlled trial
Background: Recently, several new first-line immune checkpoint inhibitors (ICIs) plus chemotherapy have been approved for patients with extensive-stage small-cell lung cancer (ES-SCLC). However, direct comparisons between first-line treatments are lacking. Therefore, we indirectly compared the effic...
Main Authors: | Youwen Zhu, Kun Liu, Hong Zhu, Hui Cao, Yangying Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-10-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/17588359231206147 |
Similar Items
-
First-line Immuno-chemotherapy for extensive-stage small-cell lung cancer: A network meta-analysis and cost-effectiveness analysis
by: Youwen Zhu, et al.
Published: (2023-03-01) -
Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis
by: Youwen Zhu, et al.
Published: (2023-01-01) -
Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy in patients with extensive-stage small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials
by: Chunlan Chen, et al.
Published: (2023-04-01) -
Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis
by: Tianming Zhang, et al.
Published: (2023-06-01) -
The predictive value of YAP-1 and POU2F3 for the efficacy of immuno-chemotherapy in extensive-stage SCLC patients
by: Yu-Qing Chen, et al.
Published: (2023-01-01)